

ENCAPSULATION OF FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE IN MICROPARTICLES OF CHITOSAN DERIVATIVE FOR COPD TREATMENT

Georgia Michailidou^a, Nina-Maria Ainali^a, Eleftheria Xanthopoulou^a, Dimitrios N. Bikiaris^a

^a Department of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124, Thessaloniki, Greece
gmichailid@chem.auth.gr




CGPM
2020

INTRODUCTION

- **Chronic obstructive pulmonary disease (COPD)** is associated with an enhanced chronic inflammation of the airways caused by tobacco smoking, air pollution or genetic factors
- **Fluticasone propionate (FLU)**: corticosteroid with high topical activity
- **Salmeterol xinafoate (SX)**: long-acting selective β_2 -adrenoceptor agonist
- FLU and SX
 - ✓ Used in COPD treatment
 - ✗ High degree of crystallinity, hydrophobic compounds.
- Inclusion of SX, FLU in polymeric microparticles results their amorphization
- **Chitosan**, a natural polysaccharide, along with its derivatives have been used for the inclusion of various pharmaceutical compounds in nano- and microparticles

EXPERIMENTAL

→ Modification of CS with 2-hydroxyethyl acrylate (2-HEA) through a free radical reaction



→ Encapsulation of Salmeterol Xinafoate (SX) and Fluticasone propionate (FLU) in CS-g-PHEA microparticles through ionic gelation technique. FLU and SX (Fig. 1 a, b) were simultaneously enclosed in their interior in 10, 20 and 30% ratios.




Fig. 1. (a) Salmeterol Xinafoate (SX), (b) Fluticasone Propionate (FLU)

RESULTS & DISCUSSION

FTIR




Fig. 2. FTIR spectra of FLU, SX, CS-g-PHEA-TPP-FLU-SX microparticles

- Characteristic FLU IR bands:**
- 1024 cm^{-1} C-F stretch
 - 1452 cm^{-1} -OH bend
 - 1715 cm^{-1} >C=O stretch

- Characteristic SX IR bands:**
- 1409 cm^{-1} -OH bend
 - 1580 cm^{-1} >N-H bend

Interactions between drugs and polymeric material

→ **Successful inclusion** of FLU and SX in CS-g-PHEA microparticles (Fig.2).

XRD




Fig. 3. XRD of FLU, SX, CS-g-PHEA-TPP-FLU-SX microparticles

Inclusion of FLU and SX in CS-g-PHEA microparticles affects the crystallinity of the drugs

→ **FLU and SX amorphization** (Fig. 3).

SEM & DLS




Fig. 4. SEM images CS-g-PHEA-TPP-FLU-SX microparticles (a) 10%, (b) 20%, (c) 30%

Fig. 4. (a-c) and Table 1. confirm the successful preparation of **spherical shaped individual micro-scaled particles**

Table 1. Size (nm) of CS-g-HEA-FLU-SX microparticles

Sample	Z-Average (d.nm)	Zeta Potential (mV)
CS-g-PHEA-TPP-10% FLU/SX	754	+26.7
CS-g-PHEA-TPP-20% FLU/SX	1005	+22.6
CS-g-PHEA-TPP-30% FLU/SX	2216	+26.6

In Vitro RELEASE




Fig. 6. In vitro release for different loading capacities of FLU from CS-g-PHEA microparticles

In vitro dissolution test of CS-g-PHEA microparticles in simulated body fluids (Fig 5 and 6).

- ✓ Sustained release of SX and FLU
- ✓ Enhancement of FLU and SX release up to 35% and 40% respectively




Fig. 5. In vitro release for different loading capacities of SX from CS-g-PHEA microparticles

CONCLUSIONS

- ✓ Modified chitosan microparticles were synthesized and FLU and SX were successfully incorporated in their interior.
- ✓ FT-IR spectroscopy evaluated the CS-g-PHEA-FLU-SX interactions, confirm a successful inclusion.
- ✓ XRD analysis showed the amorphization of FLU and SX into the microparticles.
- ✓ The prepared microparticles were of spherical shape, in micro scale.
- ✓ Sustained and enhanced release of SX and FLU was achieved

ACKNOWLEDGMENTS

The author wishes to acknowledge co-funding of this research by European Union-European Regional Development Fund and Greek Ministry of Education, Research and Religions/EYDE-ETAK through program EPAN EK 2014-2020/Action "EREVNO-DIMIOURGO-KAINOTOMO" (project T1EAK-02667).



CONTACT INFO

<https://www.linkedin.com/in/georgia-michailidou-b29699193/>

https://www.researchgate.net/profile/Georgia_Michailidou3



ORCID ID

